<DOC>
	<DOCNO>NCT00952289</DOCNO>
	<brief_summary>This randomize , double-blind study compare efficacy safety ruxolitinib ( INCB018424 ) tablets match placebo tablet patient diagnosed Myelofibrosis ( either Primary Myelofibrosis ( PMF ) Post-Polycythemia Vera Myelofibrosis ( PPV-MF ) Post-Essential Thrombocythemia Myelofibrosis ( PET-MF ) .</brief_summary>
	<brief_title>COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment : The COMFORT-I Trial</brief_title>
	<detailed_description>Patients spleen growth great 25 % base increase spleen volume Baseline eligible early unblinding , patient placebo , cross ruxolitinib prior primary study endpoint reach . If spleen growth occur Week 24 , must accompany specific worsen symptom , base worsen early satiety accompany weight loss worsen pain require daily narcotic use . After Week 24 , asymptomatic spleen growth alone sufficient early unblinding potential cross . Patients find randomized ruxolitinib early unblinding prior Week 24 discontinue . When half patient remain study complete Week 36 visit patient enrol complete Week 24 discontinue , database frozen primary analysis conduct . Once complete , patient unblinded patient randomized placebo give opportunity cross ruxolitinib treatment , provide hematology laboratory parameter adequate ; Patients receive benefit could continue treatment later market approval last randomized patient remain study complete Week 144 ( 36 month ) .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Subjects must diagnose primary myelofibrosis ( PMF ) , postpolycythemia veramyelofibrosis ( PPVMF ) postessential thrombocythemiamyelofibrosis ( PETMF ) accord 2008 World Health Organization criterion Subjects myelofibrosis require therapy must classify high risk OR intermediate risk level 2 accord prognostic factor define International Working Group Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 3 Subjects previously receive treatment Janus kinase ( JAK ) inhibitor Subjects life expectancy le 6 month Subjects inadequate bone marrow reserve demonstrate specific clinical laboratory count Subjects inadequate liver renal function Subjects clinically significant bacterial , fungal , parasitic viral infection require therapy Subjects active malignancy previous 5 year except specific skin cancer . Subjects severe cardiac condition Subjects splenic irradiation within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
	<keyword>Post-Essential Thrombocythemia Myelofibrosis</keyword>
</DOC>